Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Chief Development Officer

EVP, Chief Financial Officer

Chief Executive Officer

VP, Chief Accounting Officer

EVP, Chief Operating Officer

EVP, Drug Development

President & CCO

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-19	Premium	acquired	Premium	Premium	Premium	EVP, Chief Development Officer
2024-04-19	Premium	acquired	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-04-19	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Financial Officer
2024-04-19	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-04-03	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-13	Premium	acquired	Premium	Premium	Premium	VP, Chief Accounting Officer
2024-01-13	Premium	sold (taxes)	Premium	Premium	Premium	VP, Chief Accounting Officer
2023-11-17	Premium	bought	Premium	Premium	Premium	EVP, Chief Development Officer
2023-11-16	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-11-16	Premium	bought	Premium	Premium	Premium	EVP, Chief Financial Officer
2023-11-16	Premium	bought	Premium	Premium	Premium	EVP, Chief Development Officer
2023-10-13	Premium	acquired	Premium	Premium	Premium	VP, Chief Accounting Officer
2023-10-13	Premium	sold (taxes)	Premium	Premium	Premium	VP, Chief Accounting Officer
2023-08-22	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2023-07-25	Premium	acquired	Premium	Premium	Premium	VP, Chief Accounting Officer
2023-07-25	Premium	sold (taxes)	Premium	Premium	Premium	VP, Chief Accounting Officer
2023-07-21	Premium	bought	Premium	Premium	Premium	-
2023-07-13	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Operating Officer
2023-07-13	Premium	acquired	Premium	Premium	Premium	EVP, Chief Operating Officer
2023-07-13	Premium	acquired	Premium	Premium	Premium	VP, Chief Accounting Officer

HRTX - Heron Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for HRTX